Biology subjects

Cortese, K.

Publications and source records attributed to Cortese, K..

2 recordsLinked to original sources

bioRxiv2026

Corticospinal propagation of full-length TDP-43 toxicity drives brain-to-muscle pathology

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive degeneration of upper and lower motor neurons. Cytoplasmic inclusions containing TAR DNA-binding protein 43 (TDP-43), a key regulator of RNA metabolism, represent a pathological hallmark of all sporadic (sALS) and most familial (fALS) forms, underscoring its central role in disease pathophysiology. In affected neurons, full-length (FL) TDP-43 undergoes nuclear-to-cytoplasmic mislocalization, leading to aggregation and cellular dysfunction, and can be released to propagate pathology across neural and non-neural circuits. However, the in vivo toxicity and spreading capacity of FL TDP-43 remain poorly defined. Here, we show that purified, stable human FL TDP-43 was readily internalized by neuronal cells, where it induced aggregation and significantly reduced cell viability. In vivo, an acute unilateral stereotaxic infusion of FL TDP-43 into the rat primary motor cortex was sufficient to trigger a robust centrifugal propagation of pathology along the corticospinal axis and beyond the central nervous system (CNS). TDP-43 pathology spread from the motor cortex to the spinal cord and reached skeletal muscle. At the cellular level, propagated pathology was characterized by intraneuronal phosphorylated TDP-43 (pTDP-43) inclusions, accumulation of high-molecular-weight TDP-43 species, region-specific neurodegeneration, and pronounced mitochondrial vulnerability. Notably, skeletal muscle displayed impaired mitochondrial bioenergetics, accompanied by both motor and non-motor behavioral deficits. Collectively, our findings demonstrate neuron-to-neuron, brain-to-spinal cord and brain-to-muscle spreading of FL TDP-43 toxicity in vivo, establishing a mechanistic link between central TDP-43 pathology and peripheral dysfunction. This work identifies FL TDP-43 as an active driver of disease spreading in ALS and provides the basis for a non-transgenic, TDP-43-driven rat model of disease propagation.

neuroscience↗

bioRxiv2025

Mesodermal-specific MECP2 expression in Drosophila induces visceral and skeletal muscle defects rescued by butyrate supplementation

BackgroundPatients affected by Rett syndrome (RTT) and MECP2 duplication syndrome (MDS) experience disabling muscle weakness and gastrointestinal dysmotility of unclear origin. Whether these defects arise cell-autonomously, rather than secondarily to neural dysfunction, and which developmental windows are most vulnerable to MeCP2 disfunction remains unresolved. MeCP2 is a dosage-sensitive transcriptional regulator, whose functions are tightly linked to chromatin states. Because short-chain fatty acids (SCFAs) are known to inhibit histone deacetylases (HDACs), a tractable in vivo model is needed to test the effect of HDAC modulation on muscle defects. MethodsWe misexpressed human MECP2 in the Drosophila melanogaster mesoderm that gives rise to skeletal and visceral muscles. We analyzed quantitatively their morphology and function. To assess the effects of SCFA supplementation, we also supplemented diets with sodium butyrate (NaB), Lalbaay(R), a NaB-containing supplement, acetate (AcOH), and valproate (VPA). FindingsMECP2 misexpression caused pre-eclosion lethality, thinning of larval skeletal fibers with nuclear mispositioning and altered mitochondria. Functionally, it reduced locomotion, decreased food transit and gut peristalsis. Phenotypes were strongest when expression began during development. NaB and VPA supplementation rescue most of these phenotypes, consistent with their histone-deacetylase (HDAC) activity. Defects were not observed upon comparable misexpression of an RTT-associated MeCP2 loss-of-function variant, indicating that they might be relevant to pathogenesis of MECP2-related disorders. InterpretationOur genetic in vivo analysis models peripheral effects of MeCP2 dysregulation and their amelioration, supporting the possibility of HDAC-targeted strategies for MECP2-related muscle and gastrointestinal dysfunction.

genetics↗